Soleno Therapeutics, Inc. - Common Stock (SLNO)

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fortinet, Inc. (NASDAQ:FTNT), Roblox Corporation (NYSE:RBLX), Soleno Therapeutics, Inc. (NASDAQ:SLNO), and Simulations Plus, Inc. (NASDAQ:SLP). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -1.14% on the day to $48.05.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 2.83% on the day to $48.66.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued materially misleading business information to the investing public.

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) traded at a new 52-week high today and are currently trading at $23.03. So far today, approximately 140.58k shares have been exchanged, as compared to an average 30-day volume of 383.77k shares.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is one of today’s top gainers. The company’s shares are currently up 16.86% on the day to $4.96.

Breakthrough Results from Study C602 Soleno Therapeutics, Inc. (NASDAQ: SLNO), a trailblazer in the biopharmaceutical industry, recently unveiled its promising

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is one today’s most active stocks by volume. So far today, approximately 21.3M shares of Soleno Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 107.67k shares.

Shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) traded at a new 52-week high today and are currently trading at $22.92. So far today, approximately 20.61M shares have been exchanged, as compared to an average 30-day volume of 107.67k shares.

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.